Visit us at booth #37 to connect with our team and learn more about our Decipher Prostate and Bladder Genomic Classifiers.

We are excited to announce 17 abstracts will showcase data on Decipher Prostate, Decipher Bladder, and Decipher GRID.

See the schedule below for dates and times to view these presentations.

THURSDAY, FEBRUARY 13, 2025

8:00 AM – 9:40 AM PST

• Oral Abstract: Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA).

Review the Abstract

Presented by: Shuang Zhao, MD

Level 3, Ballroom & Live Stream

11:25 AM – 12:45 PM PST

• Poster #L10: Decipher genomic classifier (DGC) of early prostate cancer (EPC), and underlying transcriptomic profile (TP): American (Am) versus non-American (NA).

Review the Abstract

Presented by: Daniel Keizman, MD

Level 1, West Hall & On Demand

• Poster #L6: Characterizing the activity of inflammasome genes and their association with oncological outcomes in prostate cancer.

Review the Abstract

Presented by: Alireza Ghoreifi, MD

Level 1, West Hall & On Demand

• Poster #L11: Tumor necrosis factor alpha signaling activity and NCCN risk, adverse pathology, and progression during active surveillance in prostate cancer.

Review the Abstract

Presented by: Conor Driscoll, MD

Level 1, West Hall & On Demand

• Poster #F6: Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer.

Review the Abstract

Presented by: Emmanuel S. Antonarakis, MD

Level 1, West Hall & On Demand

• Poster #L5: Androgen receptor activity in biopsy specimens at initial diagnosis of prostate cancer and correlation with outcomes and treatment response.

Review the Abstract

Presented by: Nicole Handa, MD

Level 1, West Hall & On Demand

• Poster #H35: Comparison of digital pathology AI models, genomics classifier, and clinical variables in predicting progression free survival in TCGA prostate data set.

Review the Abstract

Presented by: Aidan McLoughlin

Level 1, West Hall & On Demand

• Poster: #L4: Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients.

Review the Abstract

Presented by: Daniel E. Spratt, MD

Level 1, West Hall & On Demand

• Poster #K5: PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.

Review the Abstract

Presented by: Karen E. Hoffman, MD, MHSc, MPH

Level 1, West Hall & On Demand

• Poster #L15: Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.

Review the Abstract

Presented by: Abhishek A Solanki, MD, MS

Level 1, West Hall & On Demand

• Poster #K29: Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial.

Review the Abstract

Presented by: Alan Pollack, MD, PhD

Level 1, West Hall & On Demand

• Poster #G4: Evaluating associations between genomic classifier and digital pathology–based multi-modal AI biomarkers in oligometastatic castration-sensitive prostate cancer.

Review the Abstract

Presented by: Philip A. Sutera, MD

Level 1, West Hall & On Demand

• Poster #H3: Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.

Review the Abstract

Presented by: David J Lee, MD, BA

Level 1, West Hall & On Demand

• Poster #G12: Gene expression signatures in biopsy cores as predictors of coexisting higher-grade disease in Gleason group 1 prostate cancer: Results from the Miami MAST prospective clinical trial.

Review the Abstract

Presented by: David J Lee, MD, BA

Level 1, West Hall & On Demand

FRIDAY, FEBRUARY 14, 2025

• Poster #G28: Impact of gene expression signatures of immune infiltration on response to sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guerin in high-risk non-muscle-invasive bladder cancer.

Review the Abstract

Presented by: Ian M. McElree, BS, MS (1st author is Vignesh Packiam)

Level 1, West Hall & On Demand

• Poster #G27: A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer.

Review the Abstract

Presented by: Yair Lotan, MD

Level 1, West Hall & On Demand

• Poster #H7: The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC).

Review the Abstract

Presented by: Valentina Tateo, MD

Level 1, West Hall & On Demand